Topics in HIV medicine : a publication of the International AIDS Society, USA最新文献

Occupational postexposure prophylaxis for HIV: The PEPline perspective. HIV职业性暴露后预防:PEPline视角。

Topics in HIV medicine : a publication of the International AIDS Society, USA Pub Date : 2010-12-01

引用次数: 0

Evaluating and managing cardiovascular disease risk factors in HIV-infected patients. 评估和管理艾滋病毒感染者的心血管疾病危险因素。

Topics in HIV medicine : a publication of the International AIDS Society, USA Pub Date : 2010-12-01

引用次数: 0

Recalcitrant giant molluscum contagiosum in a patient with advanced HIV disease - eradication of disease with paclitaxel. 晚期HIV患者顽固性巨大传染性软疣1例紫杉醇根治。

Topics in HIV medicine : a publication of the International AIDS Society, USA Pub Date : 2010-12-01

Silver Cree Sisneros

引用次数: 0

Update of the drug resistance mutations in HIV-1: December 2010. HIV-1耐药突变的最新进展:2010年12月。

Topics in HIV medicine : a publication of the International AIDS Society, USA Pub Date : 2010-12-01

Victoria A Johnson, Françoise Brun-Vézinet, Bonaventura Clotet, Huldrych F Günthard, Daniel R Kuritzkes, Deenan Pillay, Jonathan M Schapiro, Douglas D Richman

{"title":"Update of the drug resistance mutations in HIV-1: December 2010.","authors":"Victoria A Johnson, Françoise Brun-Vézinet, Bonaventura Clotet, Huldrych F Günthard, Daniel R Kuritzkes, Deenan Pillay, Jonathan M Schapiro, Douglas D Richman","doi":"","DOIUrl":"","url":null,"abstract":"This December 2010 version of the International AIDS Society-USA (IAS-USA) drug resistance mutations list updates the figures last published in December 2009 (Johnson VA et al, Top HIV Med, 2009;17:138-145). This update includes 9 new mutations- E138G and E138K for etravirine (Haddad M et al, CROI, 2010; Abstract 574, and Vingerhoets J et al, Antivir Ther, 2010;15 [Suppl 2]:A125); E92Q for raltegravir (Geretti AM et al, Antivir Ther, 2010;15 [Suppl 2]:A62; Cooper et al, N Engl J Med, 2008;359:355-365; and Malet I et al, Antimicrob Agents Chemother, 2008;52:1351-1358); and M36L, M36V, H69R, L89I, L89M, and L89V for tipranavir/ritonavir. In addition, the tipranavir/ritonavir N83D mutation designation was changed to boldface to indicate its recognition as a major mutation rather than a minor mutation. The mutations I13V, K20M/R, E35G, and L90M were removed from the tipranavir/ritonavir bar, reflecting new understanding. For etravirine, L100I*, K101P*, and Y181C*/I*/V* are denoted with asterisks (instead of bolded) to reflect that these individual mutations each have the greatest impact (ie, highest weighting scores) on reduced phenotypic susceptibility and impaired clinical response when compared with other etravirine mutations (Haddad M et al, CROI, 2010; Abstract 574). In addition, user notes d, n, r, w, and z were revised.","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"18 5","pages":"156-63"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29608773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States. 当前的问题在诊断和管理结核病和艾滋病合并感染在美国。

Topics in HIV medicine : a publication of the International AIDS Society, USA Pub Date : 2010-10-01

Anne F Luetkemeyer

引用次数: 0

Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection. 超越干扰素:丙型肝炎病毒感染的研究药物。

Topics in HIV medicine : a publication of the International AIDS Society, USA Pub Date : 2010-10-01

David L Wyles

{"title":"Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection.","authors":"David L Wyles","doi":"","DOIUrl":"","url":null,"abstract":"Numerous direct-acting drugs to treat hepatitis C virus (HCV) infection are in development, offering the potential for substantial improvement over current interferon alfa-based therapy and the possibility of effective interferon alfa-sparing regimens in achieving cure of HCV infection. Drugs furthest along in clinical development include HCV nonstructural protein 3 (NS3) protease inhibitors (eg, telaprevir, boceprevir), which have potent anti-HCV activity but low barriers to resistance and considerable likelihood of cross-resistance. Nucleoside analogue nonstructural protein 5B (NS5B) polymerase inhibitors exhibit a high barrier to resistance and cross-HCV genotype and subtype activity. Nonnucleoside analogue polymerase inhibitors have a low barrier to resistance and are characterized by a substantial frequency of preexisting resistance mutations. The initial use of direct-acting drugs will be as add-on treatment to interferon alfa and ribavirin regimens. The success of interferon alfa-sparing regimens will depend on presenting a sufficiently high barrier to resistance with direct-acting drugs and whether the immunomodulatory effects of interferon alfa are needed for cure of HCV infection.","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"18 4","pages":"132-6"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29493160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sexually transmitted infections and HIV: epidemiology and interventions. 性传播感染和艾滋病毒:流行病学和干预措施。

Topics in HIV medicine : a publication of the International AIDS Society, USA Pub Date : 2010-10-01

Connie L Celum

{"title":"Sexually transmitted infections and HIV: epidemiology and interventions.","authors":"Connie L Celum","doi":"","DOIUrl":"","url":null,"abstract":"Although the association of HIV and sexually transmitted infections (STIs) has been well known for 25 years, there is insufficient attention to STIs by many HIV providers, in part because patients are asymptomatic or have nonspecific symptoms and because of provider demands and focus. Optimal patient care requires frequent testing for STIs as well as obtaining an accurate medical history, which requires building trust with patients and asking direct but open-ended questions about risks and symptoms. Increased vigilance will also help practitioners avoid missing these infections. Herpes simplex virus type 2 infection has highly variable clinical manifestations, and diagnosis is needed before considering episodic or suppressive treatment. However, suppressive treatment of herpes simplex virus type 2 infection has not been shown to reduce risk of HIV acquisition. The increase in syphilis rates continues; screening is inexpensive and treatment is highly effective. Quinolone resistance rates in gonorrhea are increasing, complicating treatment in some locales. Cases of proctitis caused by chlamydial infection with lymphogranuloma venereum strains have been observed in the United States and Europe.","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"18 4","pages":"138-42"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29492701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What do we need to do to cure HIV infection. 我们需要做些什么来治愈艾滋病毒感染?

Topics in HIV medicine : a publication of the International AIDS Society, USA Pub Date : 2010-08-01

Robert F Siliciano

引用次数: 0

Dyslipidemia and its Treatment in HIV Infection. HIV感染中的血脂异常及其治疗。

Topics in HIV medicine : a publication of the International AIDS Society, USA Pub Date : 2010-08-01

Carl Grunfeld

{"title":"Dyslipidemia and its Treatment in HIV Infection.","authors":"Carl Grunfeld","doi":"","DOIUrl":"","url":null,"abstract":"HIV-infected patients have metabolic abnormalities that put them at increased risk of cardiovascular disease (CVD), including abnormalities associated with HIV infection itself, antiretroviral treatment, restoration to health, and body composition changes. The 2 major components of dyslipidemia in HIV-infected patients are hypertriglyceridemia and reduction in high-density lipoprotein (HDL) cholesterol (with likely altered function of HDL cholesterol); these abnormalities contribute to increased atherosclerotic risk. Adverse effects of antiretroviral drugs on lipids are not class specific but rather are associated with particular drugs. Thus, practitioners need to be cognizant of the risks of metabolic abnormalities posed by individual drugs. HIV infection increases CVD risk independent of the effects of traditional risk factors. The relative risk of CVD in HIV-infected patients has decreased in recent years with increasing use of lipid-lowering therapy. However, use of lipid-lowering therapy is complicated by numerous potential drug interactions with antiretroviral drugs that practitioners need to consider when prescribing lipid-lowering therapy. This article summarizes a presentation made by Carl Grunfeld, MD, PhD, at the International AIDS Society-USA continuing medical education program in Los Angeles in March 2010. The original presentation is available as a Webcast at www.iasusa.org.","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"18 3","pages":"112-8"},"PeriodicalIF":0.0,"publicationDate":"2010-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189481/pdf/nihms319935.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29329394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cervical injection drug use: a pain in the neck. 颈椎注射用药:脖子疼。

Topics in HIV medicine : a publication of the International AIDS Society, USA Pub Date : 2010-08-01

James H Tabibian, Mark Sulkowski

引用次数: 0